Novo Nordisk and Lumos Pharma side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Novo Nordisk | Lumos Pharma |
|---|---|---|
| Phase 1 | Novo Nordisk: 26 of its 43 programs at phase 1
and 21 more — sign in to see them all | Lumos Pharma: 1 of its 2 programs at phase 1 |
| Phase 2 | Novo Nordisk: 6 of its 43 programs at phase 2
and 1 more — sign in to see them all | 00% |
| Phase 3 | Novo Nordisk: 7 of its 43 programs at phase 3
and 2 more — sign in to see them all | Lumos Pharma: 1 of its 2 programs at phase 3
|
| Approved, new studies | Novo Nordisk: 4 of its 43 programs at approved, new studies
| 00% |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk24 readouts · 4 phase 3 | · | Novo Nordisk, Dec ’26: 4 programs whose next study reaches primary completion
| Novo Nordisk, Jan ’27: 8 programs whose next study reaches primary completion, 2 in phase 3
and 3 more — sign in to see them all | Novo Nordisk, Feb ’27: 1 program whose next study reaches primary completion
| Novo Nordisk, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | Novo Nordisk, May ’27: 2 programs whose next study reaches primary completion
| · | · | Novo Nordisk, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| Novo Nordisk, Sep ’27: 3 programs whose next study reaches primary completion
| Novo Nordisk, Oct ’27: 1 program whose next study reaches primary completion
|
| Lumos Pharma0 readouts · 0 phase 3 | · | · | · | · | · | · | · | · | · | · | · | · |
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Novo Nordisk
New programs 5
- NNC0662-3168 (Test product-A)phase 2 · first study · Nov 11 · Obesity
- NNC0721-5186phase 1 · first study · Nov 11 · Obesity
- NNC9836-0001phase 1 · first study · Oct 19 · Diabetes Mellitus, Type 2
- NNC0642-1895phase 1 · first study · Sep 14
- NNC0705-0002phase 1 · first study · Aug 27
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 1
- NNC4004-0002phase 1 · Jun 2026 → Jan 2027 (+8 mo) · moved Oct 26 · NCT06859073
Lumos Pharma
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.
| Condition | Novo Nordisk | Lumos Pharma |
|---|---|---|
| Obesityboth · compare here | Novo Nordisk in Obesity: 19 programs
and 14 more — sign in to see them all Their studies: Novo Nordisk’s studies of Obesity in search | Lumos Pharma in Obesity: 1 program
Their studies: Lumos Pharma’s studies of Obesity in search |
| Alzheimer Diseaseboth · compare here | Novo Nordisk in Alzheimer Disease: 1 program
Their studies: Novo Nordisk’s studies of Alzheimer Disease in search | Lumos Pharma in Alzheimer Disease: 1 program
Their studies: Lumos Pharma’s studies of Alzheimer Disease in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Novo Nordisk: 14).